JUBILANT LIFE SCIENCES LIMITED - 530019 - Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0431 Name of the Signatory :- Rajiv ShahDesignation :- Company Secretary and Compliance Officer JUBILANT LIFE SCIENCES LIMITED - 530019 - Shareholding for the Period Ended December 31, 2018
Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here Jubilant Life Sciences Ltd - 530019 - Intimation Pursuant To Regulation 50(1) And 60(2) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dear Sirs, We give the details of record date for redemption and payment of interest for Non-Convertible Debentures - STRPP I and record date for payment of interest for Non-Convertible Debentures - STRPP II, STRPP III and STRPP IV, along with date of payment. This is for your information and records. JUBILANT LIFE SCIENCES LIMITED - 530019 - Closure of Trading Window
Dear Sirs, Sub: Intimation regarding closure of Trading Window Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company will be closed for 'Designated Persons' from the close of business hours on Monday, December 24, 2018 and the same shall remain closed till 48 hours after announcement of financial results for the quarter ending December 31, 2018 to the Stock Exchanges. Accordingly, the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of closure of Trading Window. This is for your information and records. Intimation Of Investor Meetings (Non-Deal Roadshow) During December, 17 And 18, 2018
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be meeting investors/ analysts in Mumbai, India on December 17 and 18, 2018 as part of a Non-Deal Roadshow. We enclose details of investor/ analyst meetings scheduled for the same.... Jubilant Life slips 4% on USFDA inspection
This will not have any impact on the existing revenues from operations from this facility, the company said. Communication Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dear Sirs, We enclose a communication pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take the same on record. Sub.: Acquisition Of Common Stock In Inipharm Inc., USA
Dear Sirs, Further to our disclosure submitted on November 29, 2018 on the above subject, we wish to clarify that Drug Discovery and Development Solutions Limited, Singapore ('DDDSL'), a wholly-owned subsidiary of the Company, has entered into Stock Purchase Agreement on November 29, 2018 for acquiring 10% shares of Common Stock of Inipharm Inc., USA for a total purchase consideration of USD 534.20 (USD Five Hundred Thirty Four and Twenty Cents) only.... Jubilant Life Sciences inks pact to acquire Inipharm Inc for over $28 mn
The indicative time period for completion of the acquisition is three months. Announcement under Regulation 30 (LODR)-Acquisition
Re.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to the provisions of Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that subject to applicable laws, Drug Discovery and Development Solutions Limited, Singapore ('DDDSL'), a wholly-owned subsidiary company, has entered into Stock...